Scpharmaceuticals Enterprise Value Over E B I T D A from 2010 to 2024
| SCPH Stock | USD 4.75 0.08 1.66% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (4.29) | Current Value (4.50) | Quarterly Volatility 6.36726889 |
Check Scpharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scpharmaceuticals main balance sheet or income statement drivers, such as Depreciation And Amortization of 746.3 K, Interest Expense of 8.5 M or Selling General Administrative of 56 M, as well as many exotic indicators such as Price To Sales Ratio of 14.22, Dividend Yield of 0.0 or PTB Ratio of 6.81. Scpharmaceuticals financial statements analysis is a perfect complement when working with Scpharmaceuticals Valuation or Volatility modules.
Scpharmaceuticals | Enterprise Value Over E B I T D A |
Latest Scpharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Scpharmaceuticals over the last few years. It is Scpharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Scpharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Scpharmaceuticals Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (7.30) | |
| Coefficient Of Variation | (87.26) | |
| Mean Deviation | 5.63 | |
| Median | (5.06) | |
| Standard Deviation | 6.37 | |
| Sample Variance | 40.54 | |
| Range | 17.4478 | |
| R-Value | 0.73 | |
| Mean Square Error | 20.42 | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 1.04 | |
| Total Sum of Squares | 567.59 |
Scpharmaceuticals Enterprise Value Over E B I T D A History
About Scpharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Scpharmaceuticals income statement, its balance sheet, and the statement of cash flows. Scpharmaceuticals investors use historical funamental indicators, such as Scpharmaceuticals's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Scpharmaceuticals investors may use each financial statement separately, they are all related. The changes in Scpharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Scpharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Scpharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Scpharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (4.29) | (4.50) |
Currently Active Assets on Macroaxis
When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:Check out the analysis of Scpharmaceuticals Correlation against competitors. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Scpharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.454 | Quarterly Revenue Growth 1.958 | Return On Assets (0.36) | Return On Equity (1.15) |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.